Troglitazone

NF-kB pathway inhibitor; Activates PPARγ

More Views

From: 63 USD

Options

* Required Fields

Catalog # (Select a product)
NF-kB pathway inhibitor; Activates PPARγ
From: 63 USD

Overview

Troglitazone is a potent and selective activator of peroxisome proliferator-activated receptor-γ (PPARγ) with EC50 = 0.55 and 0.78 µM for human and mouse, respectively. Troglitazone does not inhibit PPARα or PPARδ at up to 10 µM (Willson et al.). Troglitazone causes cell cycle arrest at phase G1, inducing caspase-dependent apoptosis in both HeLa and hepatocellular carcinoma cell lines (Yoshizawa et al.; Chang et al.).

DIFFERENTIATION
· Stimulates adipogenesis in 3T3-L1 cells (Jeong & Yoon).
· Inhibits macrophage differentiation (Chen Y et al.).

METABOLISM
· Exerts potent glucose-lowering effects in insulin-resistant diabetic animals and in non-insulin-dependent (type II) human diabetic subjects (Lee & Olefsky).

CANCER RESEARCH
· Inhibits growth and induces apoptosis in non-small cell lung carcinoma, bladder cancer, cervical cancer, and prostate cancer cells (Chen H-M et al.; Santha et al.; Satoh et al.; Yan et al.).

· Promotes cytostatic effects in MDA-MB-231 and MCF-7 breast cancer cell lines (Berthe et al.)
Alternative Names:
Resulin; Rezulin
CAS Number:
97322-87-7
Chemical Formula:
C₂₄H₂₇NSO
"
Molecular Weight:
441.5 g/mol
Purity:
≥ 98%
Pathway:
NF-κB
Target:
PPARγ

Scientific Resources

Product Documentation

Document Type
Product Name
Catalog #
Lot #
Language

Educational Materials

(5)

Product Applications

This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.

STEMCELL TECHNOLOGIES INC.’S QUALITY MANAGEMENT SYSTEM IS CERTIFIED TO ISO 13485. PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED.